Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed

Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment

Up to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months

Up to 90% of Weight Loss Maintained Following Transition to Monthly Dosing for Three Months

Excellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to Placebo

Conference Call Scheduled for 8:00 a.m. ET Today